Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.
A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain / Nativi, Cristina; Gualdani, R; Dragoni, Elisa; DI CESARE MANNELLI, Lorenzo; Sostegni, S; Norcini, M; Gabrielli, G; LA MARCA, Giancarlo; Richichi, Barbara; Francesconi, Oscar; Moncelli, MARIA ROSA; Ghelardini, Carla; Roelens, Stefano. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - ELETTRONICO. - 3:(2013), pp. 1-10. [10.1038/srep02005]
A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain
NATIVI, CRISTINA;DRAGONI, ELISA;DI CESARE MANNELLI, LORENZO;LA MARCA, GIANCARLO;RICHICHI, BARBARA;FRANCESCONI, OSCAR;MONCELLI, MARIA ROSA;GHELARDINI, CARLA;ROELENS, STEFANO
2013
Abstract
Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.File | Dimensione | Formato | |
---|---|---|---|
srep02005.pdf
Accesso chiuso
Tipologia:
Altro
Licenza:
Open Access
Dimensione
1.31 MB
Formato
Adobe PDF
|
1.31 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.